MadeAi-LR solution now supports AI-aided Review, AI as Reviewer, Summary- and Arm-Level Extraction, and Built-in Quality Appraisal—cuts literature review time in half and delivers 90% accuracy

CapeStart, Inc. announced a major new release of MadeAi—its award-winning generative AI-based platform that expedites the synthesis of content and data for the life sciences, helping time-strapped teams to scale faster, strengthen regulatory submissions, and advance the pace of scientific research.

“Our latest release offers enhancements that so teams can scale faster and focus on what matters most: advancing science.” – Gaugarin Oliver, founder and CEO, CapeStart

Health Technology Insights: PharmaSentinel Secures License Agreement with Pay10 for Medsii.com

MadeAi first launched in November of 2024 with MadeAi-LR, a GenAI-enabled software solution leveraging the MadeAi platform to streamline key applications used in new therapy development including systematic literature reviews (SLR), clinical evidence reports, meta-analysis, targeted literature reviews , and other clinical literature assessments. MadeAi-LR cuts literature review time in half while centralizing the process with an end-to-end platform, delivering 90% accuracy, and providing sourcing and attribution along the way for verifiable, traceable, and trustworthy results.

MadeAi’s new release introduces advanced features for more complex literature review execution and content synthesis, including:

  • Support for AI-aided Review and AI as Reviewer capabilities for both Title & Abstract Screening and Full-text Screening. For the AI-aided Review mode, AI-generated suggestions are shared with two blinded human reviewers to facilitate faster, more informed decisions. For the AI as Reviewer mode, one human reviewer works in parallel with the AI, which serves as the second reviewer—reducing manual workload without compromising review quality.
  • Expanded and customizable Screening model, offering more than a dozen screening criteria including PICOS. In addition, user-defined criteria are also supported to accommodate projects with novel screening needs.
  • More dynamic Extraction, providing a Summary-level Extraction and an Arm-level Extraction. Summary-level Extraction is ideal for internal desk research, offering a consolidated view of key information from each study. For more detailed insights, Arm-level Extraction provides a granular breakdown of outcomes across different study groups, showing the user the origin of the extracted content, making reviewing and editing fast and efficient.
  • AI Agent-Enhanced Extraction, enabling the ability to extract information from text, tables, graphs, and figures.
  • Quality Appraisal built into the MadeAi workflow, allowing users to assess the risk-of-bias for included articles and visualize the results through intuitive tables and charts.

Health Technology Insights: ClinTrial Partners with Trially AI to Boost Enrollment

Developed with top 15 pharmaceutical companies, MadeAi-LR centralizes the literature review workflow, while bringing full sourcing attribution and transparency into research decision considerations. It frees teams to focus on higher-value work while driving greater productivity, stronger regulatory submissions, sharper internal strategies, and deeper research. With a single review demanding hundreds of onerous hours, MadeAi-LR helps pharma, biotech, and medtech organizations save time, stretch critical resources, and scale research to accelerate innovation.

“MadeAi-LR customers are completing more literature reviews in less time and seeing immediate ROI, and they’re eager for us to evolve our platform to address their more complex research needs,” said Gaugarin Oliver, founder and CEO of CapeStart. “Our latest release offers enhancements that allow the GenAI to support more dynamic aspects of literature review research—including AI as Reviewer, Arm-level Extraction, and Quality Appraisals, among other improvements—so teams can scale faster and focus on what matters most: advancing science.”

Since MadeAi’s launch in 2024, the platform has been recognized for AI excellence in life sciences several times over. It received a Stevie award in the 21st Annual International Business Awards program, where it was recognized as an innovative Artificial Intelligence/Machine Learning Solution in Healthcare within the Business Technology category. The platform was also named a PM360 2024 Innovator in the Generative AI Category. And most recently, MadeAi was named a winner of the 2025 Artificial Intelligence Excellence Awards, presented by the Business Intelligence Group.

Health Technology Insights: Pager Health and Protera Health Partner for Virtual MSK Care

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – businesswire